摘要
原发性肝癌是临床常见恶性肿瘤,恶性程度高、浸润和转移性强、预后差,传统手术切除以及辅助的经导管肝动脉化疗栓塞术(TACE)、射频消融和肝移植等治疗方法,有一定的局限性,对晚期肝癌疗效甚微,甚至无法开展。索拉菲尼(sorafenib)等新型分子靶向药物用于原发性肝癌治疗是近年关注焦点,本文综述相关临床疗效评价研究。
Primary liver cancer is a common malignant tumor. It is of high degree of malignancy, invasion and metastasis. The prognosis is poor and it has become a serious threat to human being health. The traditional resection operation, TACE, radiofrequency ablation and liver transplantation are auxiliary treatment methods. They all have certain limitations. The little curative effect of advanced liver cancer is not satisfied, and even can not be carried out. As a molecular targeted agent, sorafenib has been approved in many countries for the treatment of liver cancer. This review describes new molecular target agents in the therapy of liver cancer.
出处
《世界临床药物》
CAS
2015年第6期361-365,共5页
World Clinical Drug
基金
国家自然科学基金(81270515
81302788)
上海市科委重点课题(11430702400)
中国肝炎防治基金会肝病研究基金(20100021
20120005)
上海市卫生局课题(2011287
2012107)
关键词
肝癌
索拉菲尼
分子靶向药物
liver caner
sorafenib
molecular targeted agent
